These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28938574)

  • 1. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in
    Narov K; Yang J; Samsel P; Jones A; Sampson JR; Shen MH
    Oncotarget; 2017 Aug; 8(35):58504-58512. PubMed ID: 28938574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
    Jones AT; Narov K; Yang J; Sampson JR; Shen MH
    Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
    Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
    J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2
    Jones AT; Yang J; Narov K; Henske EP; Sampson JR; Shen MH
    Neoplasia; 2019 Aug; 21(8):731-739. PubMed ID: 31207499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
    Yang J; Samsel PA; Narov K; Jones A; Gallacher D; Gallacher J; Sampson JR; Shen MH
    Neoplasia; 2017 Feb; 19(2):112-120. PubMed ID: 28092822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1
    Shen MH; Samsel P; Shen LL; Narov K; Yang J; Sampson JR
    Transl Oncol; 2017 Oct; 10(5):793-799. PubMed ID: 28844017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
    Messina MP; Rauktys A; Lee L; Dabora SL
    BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
    Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
    Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A complex interplay between Akt, TSC2 and the two mTOR complexes.
    Huang J; Manning BD
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
    Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
    Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
    Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin prevents cyclophosphamide-induced ovarian follicular loss and potentially inhibits tumour proliferation in a breast cancer xenograft mouse model.
    Tanaka Y; Amano T; Nakamura A; Yoshino F; Takebayashi A; Takahashi A; Yamanaka H; Inatomi A; Hanada T; Yoneoka Y; Tsuji S; Murakami T
    Hum Reprod; 2024 May; ():. PubMed ID: 38734930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.